Author Index, Volume 95, 2000

(BR) indicates a book reviewer. Supplements are indicated by italicized page numbers preceded by supplement number in brackets, e.g.*(S2)55*

Abrams, D.B., *(S2)237*
Agrafiotis, D., 1207
Ahlström, S., 1255
Alaniz, M.L., 293(BR), 537
Alavaikko, M., *(S4)565*
Alexander, B., 1430
Allsop, S., 95
Anderson, B.J., 915
Anderson, P., *(S1)9*
Anderson, S., 23
Andréasson, S., 359
Anthony, J.C., 1719(BR)
Anton, R.F., *(S2)211*
Appleby, E., 1315
Appleby, L., 175
Araki, S., 1079
Araya, R., 294(BR)
Aricò, S., 1269
Armstrong, S., 949
Aschauer, N.H., 239
Aso, K., 529
Augustin, R., 1389

Babor, T.F., 7, 53, 193, 485, 677, 1317
Badger, G.J., 1069
Bagnardi, V., 1505
Ball, S.A., 1335
Banks, S.M., 1249
Baron, E., 1145
Barr, C., 1055
Barry, J., 1217
Basu, D., 1363
Bauer, D., 1440
Bauer, G., 375
Becker Hahn, N., 267
Berenguer, J.C., 245
Bergman, M.M., 613, 901
Berridge, K.C., *(S2)91*
Berridge, V., 23, 138(BR)
Bickel, W.K., 1069
Binmore, J., 1373
Bischof, G., 765
Blaszczynski, A., 795(BR), 1109(BR), 1583
Bloomfield, K., 1389
Boetsch, T., 1101
Bolliger, C.T., *(S1)19*
Booth, R.E., 697
Botha, A., 1430
Boudewijn Gunning, W., 737
Bourbon, D., 11
Boyd, G., 633(BR)
Brenner, V., 140(BR), 452(BR)
Brettle, R.P., 791
Brown, S.A., 1043
Bucholz, K.K., 553
Buckingham, J., 1430
Bühringer, G., 1274(BR), 1715

Carmelli, D., 427
Carroll, K.M., 219, 1335, 1710
Carter, B.L., *(S2)177*
Caskey, N.H., 1173
Casswell, S., 179, 196, 1821
Cavendish, M., 1373
Chaloupka, F.J. *(S4)477*
Chavan, B.S., 1707
Cheng, L. S.-C., 427
Christensen, H., 1833
Cisler,, R.A., 999
Clark, D.B., 1185
Coffey, C., 1679
Conklin, C.A., *(S2)145*
Cook, C.C.H., 1865
Cook, T., 136(BR)
Cooney, N.L., 889, 1107
Corrao, G., 1269, 1505
Cote, J., 719
Coutinho, R.A., 591
Crofts, N., 1864
Crome, I.B., 797(BR), 1767, 1859
Crutcher, M.B., 1430
Cummins, M., 1631
Curran, H.V., 575

Darke, S., 407, 569, 687, 1785
D'Amico, T.A., 1237
Davila, R., 115
Davoli, M., 1473
De la Fuente, J.A., 245
De las Cuevas, C., 245
de Wit, H., *(S2)165*
Déglon, J.-J., 1647
Del Boca, F.K., *(S3)347*
Dennis, M.L., *(S3)275*
Desmond, D.P., 661
Di Marino, M.E., 1185
Dickerson, M., 796(BR), 1145
Dietze, P., 1864
Donovan, D.M., 65, 1403
Douglas, R., 1706
Downey, L., 65, 1403
Drummond, D.C., *(S2)45*, *(S2)129*, *(S2)247*, 997
Dubreuil, A., 107
Dumont, K.A., *(S3)395*
Dunn, J., 1588(BR)
Dunphy, E., 1373
Dürsteler-Mac Farland, K.M., 285
Dusci, L., 437

Eadie, D., *(S4)597*
Eder, H., 239
Edwards, G., 5, 179, 296(BR), 455(BR), (S4)621, 747, 793(BR), 1113(BR), 1317, 1447(BR), 1590(BR), 1755 Eisenberger, N.I., 1173
el-Guebaly, N., 777, 949
Elander, J., 1445(BR)
Elins, J.L., 1173
Ellingstad, T.P., 749

Author Index, Volume 95, 2000

(BR) indicates a book reviewer. Supplements are indicated by italicized page numbers preceded by supplement number in brackets, e.g.*(S2)55*

Abrams, D.B., *(S2)237*
Agrafiotis, D., 1207
Ahlström, S., 1255
Alaniz, M.L., 293(BR), 537
Alavaikko, M., *(S4)565*
Alexander, B., 1430
Allsop, S., 95
Anderson, B.J., 915
Anderson, P., *(S1)9*
Anderson, S., 23
Andréasson, S., 359
Anthony, J.C., 1719(BR)
Anton, R.F., *(S2)211*
Appleby, E., 1315
Appleby, L., 175
Araki, S., 1079
Araya, R., 294(BR)
Aricò, S., 1269
Armstrong, S., 949
Aschauer, N.H., 239
Aso, K., 529
Augustin, R., 1389

Babor, T.F., 7, 53, 193, 485, 677, 1317
Badger, G.J., 1069
Bagnardi, V., 1505
Ball, S.A., 1335
Banks, S.M., 1249
Baron, E., 1145
Barr, C., 1055
Barry, J., 1217
Basu, D., 1363
Bauer, D., 1440
Bauer, G., 375
Becker Hahn, N., 267
Berenguer, J.C., 245
Bergman, M.M., 613, 901
Berridge, K.C., *(S2)91*
Berridge, V., 23, 138(BR)
Bickel, W.K., 1069
Binmore, J., 1373
Bischof, G., 765
Blaszczynski, A., 795(BR), 1109(BR), 1583
Bloomfield, K., 1389
Boetsch, T., 1101
Bolliger, C.T., *(S1)19*
Booth, R.E., 697
Botha, A., 1430
Boudewijn Gunning, W., 737
Bourbon, D., 11
Boyd, G., 633(BR)
Brenner, V., 140(BR), 452(BR)
Brettle, R.P., 791
Brown, S.A., 1043
Bucholz, K.K., 553
Buckingham, J., 1430
Bühringer, G., 1274(BR), 1715

Carmelli, D., 427
Carroll, K.M., 219, 1335, 1710
Carter, B.L., *(S2)177*
Caskey, N.H., 1173
Casswell, S., 179, 196, 1821
Cavendish, M., 1373
Chaloupka, F.J. *(S4)477*
Chavan, B.S., 1707
Cheng, L. S.-C., 427
Christensen, H., 1833
Cisler,, R.A., 999
Clark, D.B., 1185
Coffey, C., 1679
Conklin, C.A., *(S2)145*
Cook, C.C.H., 1865
Cook, T., 136(BR)
Cooney, N.L., 889, 1107
Corrao, G., 1269, 1505
Cote, J., 719
Coutinho, R.A., 591
Crofts, N., 1864
Crome, I.B., 797(BR), 1767, 1859
Crutcher, M.B., 1430
Cummins, M., 1631
Curran, H.V., 575

Darke, S., 407, 569, 687, 1785
D'Amico, T.A., 1237
Davila, R., 115
Davoli, M., 1473
De la Fuente, J.A., 245
De las Cuevas, C., 245
de Wit, H., *(S2)165*
Déglon, J.-J., 1647
Del Boca, F.K., *(S3)347*
Dennis, M.L., *(S3)275*
Desmond, D.P., 661
Di Marino, M.E., 1185
Dickerson, M., 796(BR), 1145
Dietze, P., 1864
Donovan, D.M., 65, 1403
Douglas, R., 1706
Downey, L., 65, 1403
Drummond, D.C., *(S2)45*, *(S2)129*, *(S2)247*, 997
Dubreuil, A., 107
Dumont, K.A., *(S3)395*
Dunn, J., 1588(BR)
Dunphy, E., 1373
Dürsteler-Mac Farland, K.M., 285
Dusci, L., 437

Eadie, D., *(S4)597*
Eder, H., 239
Edwards, G., 5, 179, 296(BR), 455(BR), (S4)621, 747, 793(BR), 1113(BR), 1317, 1447(BR), 1590(BR), 1755 Eisenberger, N.I., 1173
el-Guebaly, N., 777, 949
Elander, J., 1445(BR)
Elins, J.L., 1173
Ellingstad, T.P., 749

Elliott, L., 1055
Etter, J.-F., 613, 901

Farrell, M., 393, 1631
Farringdon, F., 1021
Faunce, G.J., 1438
Fergusson, D.M., 505, 1525
Ferri, M., 1473
Figueredo, A.J., *(S3)361*
Fillmore, K.M., 173, 188, 339, 355, 1271
Finch, E., 1631
Finney, J.W., 419, 833, 1491
Fischer, G., 239, 1141, 1769
Flaherty, J.A., 1805
Fountain, J., 393
Frankforter, T.L., 219, 1335
Fry, C., 1864

Ganry, O., 107
Garretsen, H.F.L., 865
Gauvin, L.M., 1249
Gerstein, D.R., 292(BR)
Gervasoni, J.-P., 1561
Giesbrecht, N., *(S4)581*
Gilchrist, G., 1055
Gill, D., 1587(BR)
Glaser, F.B., 1110(BR)
Glatt, M.M., 1275(BR)
Glautier, S., 1107
Gledhill-Hoyt, J., 1655
Gmel, G., 123, 352
Gnardellis, C., 1207
Goldberg, D.J., 931, 1055
Gordon, L.T., 219
Gore, S.M., 791
Gossop, M., 393, 1197, 1279(BR), 1631, 1720(BR)
Grace, A.A., *(S2)119*
Graham, K., 847
Grant, M., 1429
Gray, D., 11, 1469
Greenfield, T.K., 277, *(S3)329*
Grieshaber-Otto, J., *(S4)491*
Griffiths, P., 393
Grohol, J.M., 139(BR)
Gruenewald, P.J., 347, 537, *(S4)537*
Gruer, L., 931, 1055
Grun, L., 959
Gupta, N., 1363, 1707
Gwaltney, C.J., 1185

Hajek, P., 55
Halford, W.K., 1537
Hall, W., 485, 1273(BR), 1621, 1721(BR), 1765
Hansten, M.L., 1403
Hapke, U., 765
Harris, T.R., 251
Harrison, L., 1267
Harrod, M.E., 1277(BR)
Hart, K., 1373
Hastings, G., *(S4)597*
Hausser, D., 1561
Hay, A.W.M., 1771
Hay, G., 1795
Heath, A.C., 553
Heath, D.B., 1265
Hedeker, D., *(S3)381*
Heinz, A., 1868
Henson, B.R., 419
Her, Minghao, 352
Hermos, J.A., 350
Hesselbrock, V.M., 553
Hickman, M., 1351
Higgins-Biddle, J.C., 677
Hill, L., 179, 196
Hirsch, J.-M., 1161
Hirz, W., 375
Ho, A., 1647
Hodgins, D.C., 777, 949
Hodgson, R, 1716
Holder, H.D., *(S4)461*, *(S4)621*, 999
Hönigschnabl, S., 375
Horwood, L.J., 505, 1525
Howland, J., 719
Huebner, R.B., *(S3)275*
Hug, I., 285
Hughes, J.R., *(S1)3*, *(S1)9*
Hulse, G., 137(BR)
Humair, J.P., 613, 901
Hunt, W.A., *(S2)45*, *(S2)247*
Hunter, G.M., 1351
Huriwai, T., 1705
Hutchinson, S.J., 931, 1055
Hutchison, K.E., *(S2)229*

Iggy, 149, 465, 641, 803, 969, 1121, 1283, 1875
Iwamoto-Schaap, P.N., 1173

Jackson, M.C., *(S4)597*
Jacomb, P.A., 1833
Jaeger, E., 267
Jagsch, R., 239
Jang, K.L., 873
Jarvik, M.E., 1173
Jernigan, D.H., 190, *(S4)465*, 523
Job, R.F.S., 1438
John, U., 765, 1436
Johnson, R.E., 239
Joly, J.-P., 107
Jones, B.T., 1015
Jones, M., 1430
Jones, S., 1351
Jorm, A.F., 1833
Judd, A., 1351

Kalant, H., 1585(BR)
Kaskutas, L.A., *(S3)329*
Kelly, A.B., 1537
Kerimi, N., 1319, 1432
Kerr, W.C., 339, 355, 1271
Khandelwal, S.K., 1105
Klupp, N., 375
Kochi, Y., 529
Koob, G.F., *(S2)73*
Korten, A.E., 1833
Koulierakis, G., 1207
Kramer, J.R., 553
Krauss, L., 1389
Kreek, M.J., 1647
Kuebler, D., 1561
Kumpulainen, K., 1847
Kunze, M., *(S1)13*
Kwiatkowski, C.F., 697

La Harpe, R., 1647
Laakmann, G., 1101
Ladewig, D., 285
Lange, J.E., 521
Langendam, M.W., 591
Langer, M., 239
Lash, C.A., 1185
Latimer, W.W., 601
Lee, H., 1655
Lehtonen, J., 1699
Lemmens, P.H., 187
Leverton, M., 1430
Levine, H.G., 449(BR)
Li, T.-K., *(S2)55*

Lindewald, B., 359
Lintonen, T., 1255
Litt, M.D., 889, 1107
Litten, R.Z., *(S2)45*, *(S2)247*
Little, H.J, 1751
Littleton, J., *(S2)83*
Liu, K.S., 1185
Livesley, W.J., 873
Lloyd, L.V., 697
Lockyer, J., 949
Longabaugh, R., 999, 1475
Lovell, S., 1551
Lowman, C., *(S2)45*, *(S2)247*
Luthar, S.S., 1417
Lynskey, M., 1621, 1679

McBride, N., 1021
McCance, E., 1335
McCance-Katz, E.F., 219
McCarty, D., *(S3)439*
McCrady, B.S., 454(BR)
McCreanor, T., 179, 196
Macdonald, J.P., 1430
McDonald, S., 687
McEwen, A., 199, 447
McGee, R., 491
McKeganey, N., 633(BR)
McKeigue, P., 959
Mackenbach, J.P., 865
Mackintosh, A.M., *(S4)597*
McKnight, K.M., *(S3)361*
McKnight, P.E., *(S3)361*
McLellan, A.T., *(S3)281*
McLeod, R., 1708
McNeill, A., 1722(BR)
Maddux, J.F., 661
Madsen, D.C., 1173
Mäkelä, K., 727
Malhotra, A., 1363
Malhotra, R., 1363
Mangione, T.W., 719
Mann, K., 1868
Mann, R.E., 37, 60
Marsden, J., 1197, 1631
Marsh, J.C., 1237
Martin, C.S., *(S2)189*
Martin-Iverson, M., 437
Marvy, P., 339, 355, 1271
Mattick, R.P., 1277(BR)
Mattoo, S.K., 1363
Mermelstein, R.J., *(S3)381*
Meyer, C., 765
Meyer, R.E., *(S2)219*, 1763
Michie, P.T., 437
Midanik, L.T., 277
Midford, R., 1021
Miles Cox, W., 1440
Miller, W.R., 1764
Mills, C., 1055
Moffitt, T.E., 491, 1669
Monti, P.M., *(S2)229*
Montijn, S., 1430
Moos, B.S., 833
Moos, R.H., 419, 833
Morgan, C., 575
Morgenstern, J., 1475
Morse, P., 889
Moser, J., 1431
Mosher, J.F., 190
Moskalewicz, J., *(S4)505*
Müller-Spahn, F., 285
Murray, D.M., 209
Murray, R.M., 1860
Mustonen, H., 727

Naclerio, S., 1430
Neale, J., 85
Niaura, R., *(S2)155*, *(S2)189*
Nich, C., 219, 1335
Nilsson, F., 1161
Noda, T., 529
Noll, J.A., *(S3)347*
Nordlund, S., *(S4)551*

O'Brien, M., 1217
Olmstead, R.E., 1173
Opland, E., 601
Orwin, R.G., *(S3)309*
Österberg, E., *(S4)551*, *(S4)565*

Padilla, J., 245
Pandiani, J.A., 1249
Parry, C.D.H., 192
Parsons, J., 1551
Paton, S.M., 1185
Patton, G.C., 1679
Paty, J.A., 1185
Pearl, L., 1225
Pérez, R.L., 365
Perl, H.I., *(S3)275*
Perneger, T.V., 613, 901
Perret, G., 1647
Pertwee, R., 291(BR)
Peternell, A., 239
Petrakis, I.L., 219
Petry, N.M., 705, 1069, 1089
Phillips, M., 95, 1021, 1708
Picchioni, M.M., 1860
Poikolainen, K., 1505, 1766
Pothos, E.M., 1440
Poulton, R., 491, 1669
Power, K.G., 1207
Puska, P., 1699

Queval, M.-P., 107

Raistrick, D., 1771
Ramankutty, P., 1669
Ramsay, M.635(BR)
Rapkin, B.D., *(S3)395*
Raw, M., 196
Reese, A., 1389
Rehm, J., 352, 989, 1444(BR)
Rehnman, C., 359
Richman, J.A., 1805
Richmond, R., 1278(BR)
Rimpelä, A., 1255
Rimpelä, M., 1255
Risser, D., 375
Ritson, B., 1112(BR)
Robertson, J.R., 325
Robertson, R., 637(BR)
Robinson, T.E., *(S2)91*
Rodgers, B., 1833
Rogers, J.D., 277
Rohsenow, D.J., *(S2)229*, 719
Roizen, R., 188
Romanus, G., *(S4)609*
Romelsjö, A., 54, 294(BR)
Room, R., *(S4)523*, 627
Rosen, C.S., 419
Rosenberg, D.B., 1403
Rosengren, D.B., 65
Rospenda, K.M., 1805
Ross, J., 407, 569, 1785
Rossow, I., 1584
Rostami-Hodjegan, A., 1771
Rounsaville, B.J., 219, 1335
Rubbiati, L., 1505
Rumpf, H.-J., 765
Rundall, P., 1501
Ryukei, S., 529

Saggers, S., 11
Samarasinghe, D., 797(BR), 1438
Samson, H.H., *(S2)61*
San José, B., 865
San, L., 453(BR)
Sánchez-Carbonell, X., 941
Sanchez-Craig, M., 115
Sanz, E.J., 245
Sato, H., 1079, 1870
Saunders, B., 95
Sayette, M.A., *(S2)189*
Schacht, L.M., 1249
Schacter, N., *(S4)491*
Schäfer, M., 1101
Schmidt, L.A., *(S3)329*
Schneider, B., 375
Schuckit, M.A., 553
Schulze, D., 1015
Scott, R., 1055
Seaman, S.R., 791
Sears, M.R., 1669
Seifritz, E., 285
Sergeant, J.A., 737
Seus, L., 941
Shadel, W.G., *(S2)189*
Sharma, A., 1105
Sher, K.J., 631(BR)
Sheridan, J., 1551
Shiffman, S., *(S2)171*, *(S2)189*, 1185
Shimizu, S., 529
Sidani, S., *(S3)361*
Siegel, M., 719
Simpson, D., 1443(BR)
Simpson, R., 1430
Simpura, J., *(S4)505*
Sims, J., 687
Sinclair, S., *(S4)491*
Singleton, E.G., *(S2)177*
Skog, O.-J., 354, 1309
Slade, J., 1869
Smart, R.G., 37, 60
Smith, B.D., 1237
Smyth, B.P., 1217
Snow, R.W., 915
Sobell, L.C., 749, 1712
Sobell, M.B., 749, 1712
Soyka, M., 1613
Sputore, B., 11
Stellwag-Carion, C., 375
Stenbacka, M., 1573
Stenius, K., 191
Stevens, M., 1708
Stewart, D., 1197, 1631
Stichenwirth, M., 375
Stimson, G.V., 1351, 1551
Stinchfield, R.D., 601
Stockwell, T., 57, 1708
Stohler, R., 285
Störmer, R., 285
Stout, R.L., 999
Strang, J., 393, 1551, 1631
Strote, J., 1655
Suchman, N.E., 1417
Sunjic, S., 77
Sutton, S., 1111(BR)
Swan, G.E., 427
Sweanor, D., *(S1)25*

Tait, R., 437
Tanskanen, A., 1699
Tapert, S.F., 1043
Taylor, A., 931, 1055
Taylor, A.H., 199
Taylor, D.R., 1669
Thomson, A.D., 1865
Tiffany, S.T., *(S2)145*, *(S2)177*, *(S2)189*, 1106
Tigerstedt, C., 135(BR)
Toews, J., 949
Toomey, T.L., 209
Torrens, M., 1863
Treacy, S., 1197
Treno, A.J., 537, 999, *(S4)537*
Trusswell, A.S., 829, 1867
Tucker, G., 1771
Tuomilehto, J., 1699
Turnbull, P., 1551

Uchtenhagen, A., 635(BR)
Uhl, A., 375
Ussher, M.H., 199

Valentine, J., 636(BR), 1270
van Ameijden, E.J.C., 383, 591
van Benthem, B.H.B., 383
van Brussel, G.H.A., 591
van de Mheen, H., 865
van der Werf, M.J., 383
van Oers, J.A.M., 865
Vartiainen, E., 1699
Vernon, P.A., 873
Vikat, A., 1255
Vinamäki, H., 1699
Voas, R.B., 521, 1709
Vogeltanz, N.D., 251
Vycudilik, W., 375

Wagenaar, A.C., 209
Wallström, M., 1161
Warner, J., 289(BR)
Weatherburn, D., 327
Wechsler, H., 1655
Weinraub, M., 267
Weisner, C., *(S3)329*
Welch, S., 1631
Weller, C., 601
Wells, S., 847
Wells-Parker, E., 58, 915
Weninger, M., 239
West, P., 847, 1759
West, R., *(S1)29*, 141(BR), 146, 199, 447, 1277(BR)
Wheeler, C., *(S4)597*
White, R., 229
Wickes, W., 687
Wiers, R.W., 737
Wilkinson, A., 115
Willersdorf, G., 1430
Williams, S., 491
Willner, P., 1373, 1691
Wilsnack, R.W., 251
Wilsnack, S.C., 251
Wilson, D.B., *(S3)419*
Winstock, A., 1723(BR)
Winters, K.C., 601, 1770
Wirshing, W.C., 1173
Wislar, J.S., 1805
Witton, J., 296(BR)
Wodak, A., 1111(BR), 1590(BR)
Wolff, K., 142(BR), 1771
Woolfe, R., 1679
Wright, J.D., 1225
Wylie, A., 1821

Yamamoto, N., 529
Yokoyama, K., 1079
Young, R. McD., 1537

Zador, D., 77
Zambon, A., 1505
Zarkin, G.A., 1867
Zeitlin, H., 1619
Zhang, J.-F., 1821
Zweben, A., 999

Addiction

Subject Index, Volume 95, 2000

The following abbreviations have been used in this index:

(BR) Book Review
(Ed) Editorial
(L) Letter
(N&N) News & Notes

Supplement articles are indicated by italicized page numbers preceded by supplement number in brackets, e.g. *(S2)155–163*

Abstinence prior to treatment, 65–76
Addiction
  behavioural change, 1276–1277(BR)
  choice theory, 1309–1314(Ed)
  future of studies, 7–10(Ed)
  network therapy, 454(BR)
  and rationality, 449–452(BR)
Addiction Severity Index (ASI), 419–425
Addiction
  authorship, 1317–1318(Ed)
  double first for managing editor, 147(N&N)
  foreign language abstracts, 1762(Ed)
  New Year Message, 5(Ed)
  performance report (1998), 146 Adolescents
  and alcohol, 1255–1263, 1315(Ed), 1373–1388
    predictors of heavy use, 1847–1857
    selling to, 1315(Ed), 1373–1388
  drug abuse
    cannabis, 491–503, 1621–1630, 1679–1690
    Minnesota Model in treatment, 601–612
  factors implicated in substance dependence, 1043–1053
  substance misuse
    assessment, 1691–1698
    UK, 149(N&N)
  see also Young people
Age and alcohol
  mortality among white males, 1249–1254
  positive and negative experiences, 727–736
  use of drinking places, 537–551
Aggression and alcohol, 365–373, 847–863
AIDS/HIV *see* HIV
Alcohol
  Cochrane Review Group on Drugs and, 1473–1474 (Ed)
  Communities Mobilizing for Change on (CMCA), 209–217
  consumption
    binging, 521–528, 640(N&N)
    cigarettes, coffee and suicide risk, 1699–1704
    and crime, 1525–1536
    drinkers and drinking places in literature, 1447(BR)
    effects on merchant ship operation, 719–726
    following natural disasters, 529–536
    gender differences and cross-cultural patterns, 251–265
    habits among adolescents, Finland, 1255–1263
    negative and positive experiences, 727–736
    patterns and health outcomes, 865–872
    personality, family environment and, 873–888
    psychiatric symptoms and deviance as predictors, 1847–1857
    risk factors for depression and anxiety, 1833–1845
    sexual harrassment and work-place abuse, 1805–1820
    successful drinking or drinking among the successful, 1584(L)
  craving *see* Alcohol craving research
  cue-reactivity, *(S2)129–144*
    in social drinkers, 1015–1020
  dependence *see* Alcoholism
  education
    in American schools, 138–139(BR)
    medical training, 802–803(N&N)
    school health project, 1021–1042
  excise duty, South Africa, 801–802(N&N)
  expectancies in school children, 737–746
  and heart disease, 1505–1523
    deaths from binging, 640(N&N)
    moderate drinking as protective factor, 173–174(Ed), 301(N&N)
  interventions

Alcohol (*cont*)
effects of coping strategies on drinking outcome, 115–22
indigenous Australians, 11–22, 1118(N&N)
putting thiamine in beer, 1865–1866(L)
screening and, 667–686
licensing, 327(Ed)
restrictions and indigenous Australians, 1469–1472(Ed), 1705–1707(L)
selling to the underaged, 1315(Ed), 1373–1388
UK laws relaxed, 997–998(Ed)
mortality, 989–995(Ed), 1249–1254
cirrhosis, 339–346, 347–358, 1267–1272(L)
policies
European and Nordic, 135–136(BR)
ICAP, 179–185(Ed), 187–96, 627–629(L), 1265–1267(L), 1429–1438(L)
India, 148(N&N)
Japan, 1593–1594(N&N)
treatment to management, 136(BR)
UK, 997–998(Ed), 1110(BR)
unrecorded consumption and, (S4)551–564
see also under Alcohol supply problems
aggression, 365–373, 847–863
cirrhosis, 339–346, 347–358, 1267–1272(L)
heart disease, 640(N&N), 1505–1523
medical training in, 802–803(N&N)
onset of use and, Germany, 1389–1401
prevalence among elderly hospital patients, 107–113
prevention in South East Asia, 1594(N&N)
risk of injury, 1707–1709(L)
prohibition enforcement, 1590–1591(BR)
and public health in developing countries, 797(BR)
research
data collection mode and non-response, 123–134
eco-epidemiology for, 53–54
new UK centre for, 1727–1728(N&N)
telephone vs. face-to-face interview modes, 277–284
see also Alcohol craving research; Health services research risk functions for negative consequences, 1821–1832
as a stimulant drug, 1751–1753(Ed)
see also Drink-driving; Drinking places; Substance abuse; Women
Alcohol craving research, *(S2)45–54*
animal models, *(S2)55–128*
craving and relapse, *(S2)55–60*
ethanol, *(S2)73–81*
ethanol drinking, microstructure, *(S2)61–72*
incentive-sensitization view, *(S2)91–117*
relapse prevention, *(S2)83–90*
tonic/phasic dopamine system regulation, *(S2)119–128*
human models, *(S2)171–175*
cognitive processing model, *(S2)145–153*
cue-reactivity, *(S2)129–144*
social drinkers, *(S2)165–169*
methodological approaches
craving relevant variables, *(S2)177–187*
obsessive compulsive aspects, *(S2)211–217*
synthesizing perspectives, *(S2)219–227* , *(S2)247–255*
biological, psychobiological and psychosocial models, *(S2)229–236*
neuroscience, behavioural and clinical science, *(S2)219–227*
transdisciplinary concepts and measures, *(S2)237–246*
Alcohol supply, *(S4)461–463* , *(S4)621–627*
alcopops in Sweden, *(S4)609–619*
ambiguous role of alcohol, *(S4)523–535*
commercial interests and alcohol policies, *(S4)565–579* , *(S4)581–595*
commodity chain analysis, *(S4)465–475*
implications of international tobacco supply issues, *(S4)477–489*
international treaties and alcohol regulation, *(S4)491–504*
local and global, *(S4)537–549*
marketing to young people, *(S4)597–608*
in transitional societies, *(S4)505–522*
unrecorded consumption and alcohol control, *(S4)551–564*
see also Partnership
Alcoholism
adult children of alcoholics, 267–276, 631–633(BR)
age and mortality among white males, 1249–1254
and antisocial personality disorder, 553–567
characteristics, etiology, treatments and controversies, 1444–1445(BR)
family history, and neuropsychological functioning, substance dependence, 1043–1053

Alcoholism (*cont*)
history of, 455(BR)
'natural recovery' from, 765–775
psychological theories of drinking and, 1274–1275(BR)
recovery model, 633(BR)
relapse in severely dependent male, 95–106
and schizophrenia, 1613–1618(Ed), 1859–1863(L), 1868–1869(L)
Stroop colour-naming task, 1438–1442(L)
treatment
12-step guide, 1275–1276(BR)
—cocaine users, 1335–1349
cognitive-behavioural, 1475–1490, 1710–1717(L)
community initiatives evaluation, 463(N&N)
effects of high-risk programs, 37–52, 53–64
and importance of economic analysis, 1867–1868(L)
limitations in using existing trials to develop practice guidelines, 1491–1500
medical care costs, 999–1013
predictors of craving following, 889–900, 1106–1108(L)
America *see* United States (US)
Amphetamine abuse, treatment, 229–238
Amsterdam, methadone maintenance and cessation, 591–600
Anaemia, in HIV-positive and HIV-negative drug users, 383–392
Antidepressants, use among injecting drug users, 407–417
Antisocial personality disorder, and alcoholism, 553–567
ASI *see* Addiction Severity Index
Attitudes Towards Smoking Scale (ATS-18), 613–625
Australia
antidepressant use among injectors, 407–417
cannabis use in adolescents, 1679–1690
deaths
heroin overdoses from non-injecting routes, 569–573
methadone maintenance treatment, 77–84
drug use in, harm minimization, 1590(BR)
heroin injecting rooms, 300(N&N), 1729(N&N)
Wernicke—Korsakoff syndrome, 829–832(Ed)
Australian Aboriginals
alcohol misuse interventions, 11–22, 1118(N&N)
liquor licensing restrictions, 1469–1472(Ed), 1705–1707(L)
Austria, heroin quality and heroin-related deaths, 375–382

Behavioural change, 1276–1277(BR)
Benzodiazepine dependence, 245–250
among heroin users, 1785–1793
Blood-borne viruses *see* Hepatitis C; HIV
Brazil
cannabis crop eradication, 464–465(N&N)
cigarette advertising, 1729(N&N)
drug use survey, 1728–1729(N&N)
government, corruption and drug barons, 464(N&N)
Bromocriptine, smoking reduction, 1173–1183
Buprenorphine
male addicts in India, 1363–1372
treatment of opioid-dependency
dosing regimens, 1069–1077
pregnant women, 239–244

Caffeine in cola, 1730(N&N)
Canada
cannabis-growing contract, 1281–1282(N&N)
cigarette health warnings strengthening, 803(N&N)
tobacco control research network, 1119–1120(N&N)
workplace drug and alcohol testing, 1729–1730(N&N)
Cannabis
adolescent use, 1679–1690
and educational attainment, 1621–1630
crop eradication, Brazil, 464–465(N&N)
crop-growing contract, Canada, 1281–1282(N&N)
and driving, UK, 639–640(N&N)
ID card scheme, 801(N&N)
increased use at US colleges, 1655–1667
legal status, NZ, 1117(N&N)
and medicine, 291–292(BR)
and mental health, 491–503
new journal, 641(N&N)
production and trade regulation, Netherlands, 148(N&N)
and public health, 485–490(Ed)
respiratory effects of dependence, 1669–1677
and use of other illicit drugs, 505–520

Catalonia, heroin addicts' survival, 941–948
Children
  alcohol expectancies, 737–746
  alcohol harm, school health project, 1021–1042
  of alcoholics, 267–276, 631–633(BR)
  substance use habits in UK, 149(N&N)
  see also Women, with children
China, predicted smoking epidemic, 147(N&N)
Choice theory, 1309–1314(Ed)
Cigarettes *see* Smoking; Tobacco
CMCA *see* Communities Mobilizing for Change on Alcohol Cocaine
  —alcohol users, treatments, 1335–1349
  characteristics of 'new users', 1561–1571
  crack mothers, 137–138(BR)
  history of, 296–297(BR)
  —methadone maintained opioid addicts, treatment, 219–228
Cochrane Review Group on Drugs and Alcohol, 1473–1474(Ed)
Coffee, alcohol, cigarettes and suicide risk, 1699–1704
Cognitive processing model, alcohol craving, *(S2)145–153*
Cognitive social learning theory, drug craving, *(S2)155–163*
Cognitive-behavioural treatment, alcoholism, 1475–1490, 1710–1717(L)
Communities Mobilizing for Change on Alcohol (CMCA), 209–217
Coronary disease *see* Heart disease
Costs, alcoholism treatment, 999–1013
Crack mothers, 137–138(BR)
Craving *see* Alcohol craving research; Drug(s), research, craving Crime, and alcohol abuse, 1525–1536

Developing countries
  alcohol and public health in, 797(BR)
  alcohol supply, commodity chain analysis, (S)465–475
  see also specific countries
Dexamphetamine substitution, 229–238
Disulfiram treatment, 219–228, 1335–1349
Dopamine system regulation, tonic/phasic model, *(S2)119–128*
Drink-driving
  prevention, 209–217, 1445–1446(BR)
  screening, 915–929, 1709–1710(L)
Drinking places
  aggression in, 847–863
  in literature, 1447(BR)
  over-serving in, 359–363
  use by gender, age and ethnic group, 537–551
Drug Treatment and Testing Orders (DTTO), 801(N&N)
Drug(s)
  Cochrane Review Group on, and Alcohol, 1473–1474(Ed)
  and law, 1113(BR), 1721–1722(BR)
  misuse, 637–638(BR), 1225–1235
    capture—recapture estimates, 1795–1803
    co-morbidity research, 1619–1629(Ed)
    community prevention initiatives, 640–641(N&N)
    consumer magazine, 968(N&N)
    dependence or addiction, 661–665(Ed)
    ethnic groups, 969(N&N)
    European scene, 294–295(BR), 633–634(BR)
    harm reduction conference, 1117–1118(N&N)
    suicidal intent in overdose, 85–93
    and suicide, 175–177(Ed)
    surveys, 299(N&N), 1728–1729(N&N)
    and young people, co-morbidity research, 1619–1629(Ed)
    see also Injectors; Substance abuse
  organizations, 1595–1596(N&N)
  origins and interventions, 1719–1720(BR)
  policy, Spain, 464(N&N)
  polydrug, 219–228, 705–717, 1197–1206
  research
    craving, *(S2)155–163* , *(S2)189–210*
    improvement strategies, *(S3)281–308*
    meta-analyses in treatment, *(S3)419–438*
  role of competence factors, 1573–1581
  routes, 1197–1206
  treatment
    availability affects on population health, 55–57
    clinical management guidelines, 325–326(Ed)
    disulfiram, 219–228, 1335–1349
    diversion of prescribed drugs by users, 393–406
    improving social services for mothers, 1237–1247
    international perspective, 634–635(BR)
    psychotherapy, 1335–1349
    and testing orders (DTTO), 801(N&N)
  women *see* Women
  see also specific drugs
Dublin, opiate smoking, 1217–1223

DUI (Driving under the influence) *see* Drink-driving

Edinburgh, recidivism rate of injectors, 791–793(L)
Elderly, prevalence of alcohol problems, 107–113
EMCDDA *see* European Monitoring Centre for Drugs and Drug Addiction EMETYST Project, 941–984
England *see* United Kingdom (UK)
Ethanol drinking, animal models, *(S2)61–72*, *(S2)73–81*
Ethnic groups
  drug use, 969(N&N)
  research partnership, Hawaii, 1728(N&N)
  substance abuse prevention, 293–294(BR)
  use of drinking places, 537–551
Europe, Central and Eastern, alcohol supply, *(S4)505–522*
European Alcohol Action Plan, 802(N&N)
European drug scene
  night life, 633–634(BR)
  patterns, 294–295(BR)
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
  key legislation CD-ROM, 969(N&N)
  publication, 149(N&N)
European and Nordic alcohol policies, 135–136(BR)
Exercise and smoking cessation, 199–208

Family environment, 267–276, 873–888
Family history, 1043–1053
Finland
  drinking habits, adolescents, 1255–1263
  economic interests and alcohol control policy, *(S4)565–579*
France, wine consumption and cirrhosis mortality (Iguana Column), 465(N&N)

Gambling effective interventions guide, 795–796(BR)
  government lotteries, 959–966, 1583(L)
  natural vs. treatment-assisted recovery, 777–789
  pathological, 796–797(BR)
  psyche, 1109–1110(BR)
  research issues, 1145–1159
  socioeconomic impacts and public policy, 292–293(BR)
  substance abusers and HIV risk, 1089–1100
Gender and alcohol
  cross-cultural patterns, 251–265
  positive and negative experiences, 727–736
  use of drinking places, 537–551
Germany, alcohol use and problems, 1389–1401
Glasgow, injecting risk behaviour, 931–940
Greek prisons, 1207–1216

Harm reduction
  alcohol, 11–22, 1118(N&N)
  conference, 1117–1118(N&N)
  drug use, 1590(BR)
  injectors, 1351–1361, 1588–1589(BR)
  smoking policy interventions, *(S1)9–11*
  strategies, 635–636(BR), 1277–1278(BR)
Hawaii, 1728(N&N)
Health behaviour change, 1111–1112(BR), 1120–1121(N&N)
Health services research
  assessing program fidelity, *(S3)309–327*
  evaluating policy changes *(S3)329–345*
  follow-up rates and treatment outcomes, 1403–1416
  group methods, *(S3)395–418*
  improvement strategies, *(S3)281–308*
  longitudinal substance use outcomes, *(S3)381–394*
  meta-analyses of treatments, *(S3)419–438*
  multivariant modeling of missing data, *(S3)361–380*
  state-of-the-art methodologies, *(S3)275–280*
  on treatment, *(S3)439–447*
  validity of self-reported data, *(S3)347–360*
Heart disease, 1505–1523
  deaths from binging, 640(N&N)
  moderate drinking, 301–302(N&N)
    as protective factor, 173–174(Ed), 301(N&N)
Hepatitis C
  naloxone distribution and transmission of, 1864–1865(L)
  psychosis in interferon-alpha treatment of, 1101–1104
Heroin addicts
  benzodiazepine dependence, 1785–1793
  characteristics of 'new', 1561–1571
  medical prescription of narcotics, 793–795(BR)
  oxygen saturation, 285–287(L)
  smoking route, 1217–1223
  survival, Spain, 941–948
  treatment of pregnant women, 239–244, 1141–1144(Ed)

see also Injectors; Methodone maintenance
Heroin injecting rooms, Australia, 300(N&N), 1729(N&N)
Heroin-related deaths
from non-injecting routes, 569–573
and heroin quality, 375–382
unexplained, 1595(N&N)
History
alcoholism, 455(BR)
classic text revisited, 289–290(BR), 1273–1274(BR)
cocaine, 296–297(BR)
opium
pharmaceutical regulation, UK, 1585–1587(BR)
Turkmenistan, 1319–1333
UK, 23–36, 1585–1587(BR)
HIV
anaemia in drug users, 383–392
in former USSR, 299(N&N)
social networks and drug injectors, 1279–1280(BR)
substance abuse and psychiatric problems, 797–798(BR)
HIV risk behaviour
gambling in substance abusers and, 1089–1100
injectors, 697–704, 931–940, 1207–1216, 1279–1280(BR), 1351–1361
Holland *see* Netherlands

Ibogaine treatment for drug addiction (Iguana column), 149(N&N), 803(N&N), 1121(N&N)
ICAP *see* International Centre for Alcohol Policies
IDU (injecting drug users) *see* Injectors
India
alcohol issues, 148(N&N)
buprenorphine addicts, 1363–1372
tobacco advertising, 301(N&N)
Injecting rooms, Australia, 300(N&N), 1729(N&N)
Injectors
antidepressant use among, 407–417
effects of offering free treatment, 697–704
harm reduction, 1588–1589(BR)
naloxone distribution and hepatitis C transmission, 1864–1865L
pharmacy-based needle exchange schemes, 1551–1560
recidivism rate, 791–792(L)
risk behaviour, 697–704, 931–940, 1207–1216, 1279–1280(BR), 1351–1361
social networks, HIV/AIDS, 1279–1280(BR)
see also Heroin addicts; Methadone maintenance
Interferon-alpha treatment of hepatitis C, 1101–1104
International addiction journal editors, 1593(N&N)
International Centre for Alcohol Policies (ICAP), 179–185(Ed), 187–96, 627–629(L), 1265–1267(L), 1429–1438(L)
International drug control, US, 1113(BR)
International Society of Addiction Medicine and co-operation with the drinks industry (Iguana column), 969(N&N)
Internet
addiction, 139–140(BR), 452(BR)
implications, 140–141(BR)
resources, mental health guide, 296(BR) tobacco companies documents, 461(N&N)
Interviews
Jim Rankin, 667–676
Joy Mott, 329–337
Israel, smoking ban in hospitals, 803(N&N)

Japan
alcohol
consumption following natural disasters, 529–536
control policy, 1593–1594(N&N)
smoking
and health survey, 461–462(N&N)
prevalence, 1079–1088
Jellinek Award, 1282(N&N)

Ketamine, effects, 575–590

Law and drugs, 1113(BR), 1721–1722(BR)

Marijuana *see* Cannabis
Maternal addiction *see* Women, with children; Women, pregnant
Medical education, substance-related disorders, 949–957
Mental health and cannabis use, 491–503
Methadone maintenance, 1111(BR)
cessation of injecting drug use, 591–600
cognitive impairment, 687–695
deaths, 77–84, 1647–1653
disulfiram treatment for cocaine dependence, 219–228
GP-centred programme, 1055–1068
injectable vs. oral, 1631–1645, 1863–1864(L)
monitoring, 1771–1783

psychosis during interferon-alpha treatment of hepatitis C, 1101–1104
Methamphetamine, fetal exposure, 1120(N&N)
Mexico
binging by youth, 521–528
fiesta tradition, 365–373
Minnesota Model, treatment of adolescent drug users, 601–612
Mott, Joy (interview), 329–337

Naloxone distribution and hepatitis C transmission, 1864–1865(L)
National Institute on Drug Abuse (NIDA)
clinical trials network, 464(N&N)
club drug prevention initiatives, 299–300(N&N)
drug addiction treatment publication, 641(N&N)
'Natural recovery', 747(Ed)
methodological review, 749–764
sample selection bias, 765–775
vs. treatment-assisted recovery, 777–789
Nepal, women with alcohol-related problems, 1105–1106(L)
Netherlands
cannabis, production and trade regulation, 148(N&N)
methadone maintenance and cessation, 591–600
passive smoking ruling, 1119(N&N)
Network therapy, 454(BR)
New Zealand
alcohol-related negative consequences, 1821–1832
legal status of cannabis, 1117(N&N)
NGO perspective on partnership, 1501–1504
Nicotine replacement therapy, (S)13–17
regulatory barriers to licensing, *(S1)29–34*
regulatory imbalance, *(S1)25–28*
sublingual tablet, 1161–1171
transdermal patches, 1185–1195
NIDA *see* National Institute on Drug Abuse

Obsessive Compulsive Drinking Scale, *(S2)211–217*
Office of National Drug Control Policy (ONDCP), 639(N&N)
Opiates *see* Heroin addicts; History, opium; Injectors

Partnership
ICAP, 179–185(Ed), 187–96, 627–629(L), 1265–1267(L), 1429–1438(L)
NGO perspective, 1501–1504
see also Alcohol supply
Personality disorder traits, 873–888
Pharmacy-based needle exchange (PBNX) schemes, 1551–1560
Poland
community prevention initiatives, 640–641(N&N)
policies against tobacco companies, 300–301(N&N)
Polydrug misuse, 219–228, 705–717, 1197–1206
Pregnancy *see* Women, pregnant
Prohibition traduced (Iguana column), 1283(N&N)
Problem drinking *see* Alcoholism
Project MATCH, 999–1013
Psychiatric symptoms, predictor of heavy alcohol use, 1847–1857
Psychiatry guide, 1112–1113(BR)
Psychotherapy
and consumerism, 1723–1724(BR)
disulfiram and, for cocaine-alcohol users, 1335–1349
Public health
alcohol supply issues, *(S4)621–627*
cannabis use and, 485–490
tobacco companies, 1869–1872(L)

Rankin, Jim (interview), 667–676
Rationality and addiction, 449–452(BR)
Research
checklist for writing up reports, 1759–1762(Ed)
group-randomized trials, 636–637(BR)
see also Alcohol craving research; Drug(s), research; Health services research
Risk behaviour
alcohol consumption, 1707–1709(L)
see also HIV risk behaviour
Rolleston Committee Report, 1273–1274(BR)
Russia, HIV rate, 299(N&N)

Schizophrenia and alcoholism, 1613–1618(Ed), 1859–1863(L), 1868–1869(L)
Scotland

capture-recapture estimates of drug misuse, 1795–1803
injecting risk behaviour, 931–940
recidivism rate of injectors, 791–793(L)

Screening instruments
benzodiazepine dependence, 245–250
driving under the influence (DUI), 915–929, 1709–1710(L)
substance misuse in adolescents, 1691–1698
Severity of Dependence Scale (SDS), 245–250
Shopping, psychotherapy and consumerism, 1723–1724(BR)
Smoking
alcohol, coffee and suicide risk, 1699–1704
Attitudes Towards Smoking Scale (ATS-18), 613–625
Canada
health warnings strengthening, 803(N&N)
Ontario Tobacco Research Unit (OTRU), 1119–1120(N&N)
China, epidemic predicted, 147(N&N)
education
medical students, 141(BR)
and prevention programme, 1722–1723(BR)
resources, 1120(N&N)
effects on Sternberg visual memory search paradigm, 437–446
genetic analysis, 427–435
Israeli hospitals, ban in, 803(N&N)
Japan
prevalence, 1079–1088
survey, 461–462(N&N)
passive, 1118–1119(N&N)
and philately, 1595(N&N)
political history of, 1443–1444(BR)
reduction, *(S1)3–7*, 1278–1279(BR)
bromocriptine, 1173–1183
dissonant smokers, *(S1)13–17*, 1587–1588(BR)
and exercise, 199–208
new clinical practice guidelines, 1595(N&N)
policy interventions, *(S1)9–11*
practical experiences in, *(S1)19–24*
primary care treatment, 1282–1283(N&N)
recruitment for clinical trials, 447(Ed)
see also Nicotine replacement therapy
self-efficacy, 901–913
South Africa, restrictions, 461(N&N)
US FDA cannot regulate, 967(N&N)
see also Tobacco
South Africa
alcohol excise duty, 801–802(N&N)
drug use survey, 299(N&N)
tobacco control regulations, 461(N&N)
South East Asia, prevention of alcohol problems, 1594(N&N)
Spain
drug policy, 464(N&N)
heroin addicts' survival, 941–948
Spanish language abstracts, *Addiction* , 1762(Ed)
Sternberg visual memory search paradigm, smoking effects, 437–446
Stockholm, licensed premises, 359–363
Stroop colour-naming task, 1438–1442(L)
Substance abuse, 142(BR)
adolescents *see* Adolescents
care, 833–846
harm reduction strategies, 635–636(BR), 1277–1278(BR)
HIV
and psychiatric problems, 797–798(BR)
risk and gambling, 1089–1100
medical education in related disorders, 949–957
prevention, 293–294(BR)
research *see* Health services research
Suicide
and drug misuse, 175–177(Ed)
intent in non-fatal illicit drug overdose, 85–93
risk and alcohol, cigarettes and coffee, 1699–1704
Sweden
alcopops in, *(S4)609–619*
competence factors role in reducing future drug misuse, 1573–1581
Stockholm, licensed premises, 359–363
Switzerland
Hidden Population Study, 1561–1571
lethal methadone intoxications, 1647–1653
reported alcohol consumption, 123–134

TACADE and the drinks industry (Iguana column), 641(N&N)
Therapeutic community, 1720–1721(BR)
Tobacco advertising
Brazil, 1729(N&N)
India, 301(N&N)
South Africa, 461(N&N)
Tobacco companies
commercial vs. public health interests, 1869–1872(L)

documents online, 461(N&N)
passive smoking, 1118–1119(N&N)
Poland, policies against, 300–301(N&N)
US legal investigations, 147–148(N&N)
Tobacco control research network, Canada, 1119–1120(N&N)
Tobacco litigation, 967–968(N&N)
Tobacco supply issues, *(S4)477–489*
Tobacco, *see also* Smoking
Treatment, 453(BR)
abstinence prior to, 65–76
making of large claims, 1755–1757(Ed), 1763–1770
managed care, 1763–1764
obstruction of progress, 1766–1767
—prevention divide, 57–58
professional ethics, 1769
and marketing, 1764–1765
responsibility for dissemination of research findings, 1767–1769
UROD, 1765–1766
warning label, 1770
see also under Alcoholism; Drug(s); *specific addictions*

United Kingdom (UK)
alcohol licensing laws relaxed, 997–998(Ed)
alcohol policy, 1110(BR)
Centre for Alcohol Research, new, 1727–1728(N&N)
drug misuse, 637–638(BR)
and dependence, clinical management guidelines, 325–326(Ed)
diversion of prescribed drugs by users in treatment, 393–406
magazine, 968(N&N)
regional variations in routes, 1197–1206
risk behaviour of injectors, 1351–1361
Drug Treatment and Testing Orders (DTTO), 801(N&N)
gambling and national lottery, 959–966
substance use by schoolchildren, 149(N&N)
see also Scotland
United States (US)
alcohol education in schools, 138–139(BR)
cannabis and other drug misuse at colleges, 1655–1667
commercial interests and alcohol policies, *(S4)581–595*
drug and alcohol treatment publications, 641(N&N)
FDA cannot regulate cigarettes, 967(N&N)
heart disease and moderate drinking, 301–302(N&N)
international drug control, 1113(BR)
marijuana ID card scheme, 801(N&N)
Office of National Drug Control Policy (ONDCP) and entertainment networks, 639(N&N)
tobacco companies legal investigations, 147–148(N&N)
see also National Institute on Drug Abuse (NIDA) USSR, former *see* Russia

Vienna, heroin quality and heroin-related deaths, 375–382

Wernicke–Korsakoff syndrome, 829–832(Ed)
Wine consumption and cirrhosis mortality in France (Iguana column), 465(N&N)
Women
alcohol problems of maritally distressed, 1537–1549
alcohol problems in Nepal, 1105–1106(L)
alcohol and violence against, Mexico, 365–373
attachment in adult daughters of alcoholic fathers, 267–276
with children
crack mothers, 137–138(BR)
drug abuse treatment improvement, 1237–1247
parenting behaviours, 1417–1428
pregnant
fetal exposure to methamphetamine, 1120(N&N)
treatment of opioid-dependence, 239–244, 1141–1144(Ed)
Workplace drug and alcohol testing, 1729–1730(N&N)

Young people
alcohol marketing to, *(S4)597–608*
alcohol-related aggression in bars, 847–863
alcopops in Sweden, *(S4)609–619*
binge drinking, 521–528
drug use
co-morbidity research, 1619–1629(Ed)
competence factors role in reducing future, 1573–1581
experience and knowledge of illicit, 1225–1235
night life in Europe, 633–634(BR)
respiratory effects of cannabis dependence, 1669–1677
US NIDA drug prevention initiatives, 299–300(N&N)
see also Adolescents